Asia Pacific Infectious Disease Therapeutics Market
The Asia Pacific Infectious Disease Therapeutics Market size was valued at US$ 25,904.61 Mn in 2022 and is projected to reach US$ 37,415.07 Mn by 2030, growing at a CAGR of 4.7% during 2022 - 2030.
Report Coverage
- Drug Class: Anti-viral, Anti-Bacterial, Anti-Fungal
- Indication: HIV, Hepatitis, Tuberculosis, Influenza, HPV
- Distribution Channel: Hospital Pharmacies, Retail Pharmacies
US$ 25,904.61 Mn
Market size in 2022
US$ 37,415.07 Mn
Market Size by 2030
4.7%
CAGR, 2022 - 2030
2023-2030
Forecast Period
1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Infectious Disease Therapeutics Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Infectious Disease Therapeutics Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Infectious Disease Therapeutics Market Regional Analysis
6.2 Asia Pacific Infectious Disease Therapeutics Market Revenue 2020-2030 (US$ Million)
6.3 Asia Pacific Infectious Disease Therapeutics Market Forecast Analysis
7. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Drug Class
7.1 Anti-viral
- 7.1.1 Overview
- 7.1.2 Anti-viral: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.2 Anti-Bacterial
- 7.2.1 Overview
- 7.2.2 Anti-Bacterial: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
7.3 Anti-Fungal
- 7.3.1 Overview
- 7.3.2 Anti-Fungal: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Indication
8.1 HIV
- 8.1.1 Overview
- 8.1.2 HIV: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.2 Hepatitis
- 8.2.1 Overview
- 8.2.2 Hepatitis: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.3 Tuberculosis
- 8.3.1 Overview
- 8.3.2 Tuberculosis: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.4 Influenza
- 8.4.1 Overview
- 8.4.2 Influenza: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
8.5 HPV
- 8.5.1 Overview
- 8.5.2 HPV: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
9. Asia Pacific Infectious Disease Therapeutics Market Analysis – by Distribution Channel
9.1 Hospital Pharmacies
- 9.1.1 Overview
- 9.1.2 Hospital Pharmacies: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
9.2 Retail Pharmacies
- 9.2.1 Overview
- 9.2.2 Retail Pharmacies: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast, 2020-2030 (US$ Million)
10. Asia Pacific Infectious Disease Therapeutics Market – Asia-Pacific Analysis
10.1 Overview
10.2 Asia-Pacific- 10.2.1 Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Key Country, 2023 and 2030 (%)
- 10.2.1.1 Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast Analysis – by Country
- 10.2.1.1 China: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.1.1 China: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.1.2 China: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.1.3 China: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.2 India: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.2.1 India: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.2.2 India: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.2.3 India: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.3 Japan: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.3.1 Japan: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.3.2 Japan: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.3.3 Japan: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.4 Australia: Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.4.1 Australia: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.4.2 Australia: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.4.3 Australia: Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
- 10.2.1.5 Rest of Asia-Pacific : Asia Pacific Infectious Disease Therapeutics Market – Revenue and Forecast to 2030 (US$ Million)
- 10.2.1.5.1 Rest of Asia-Pacific : Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Drug Class
- 10.2.1.5.2 Rest of Asia-Pacific : Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Indication
- 10.2.1.5.3 Rest of Asia-Pacific : Asia Pacific Infectious Disease Therapeutics Market Breakdown, by Distribution Channel
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 AbbVie Inc
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Astellas Pharma Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Bayer AG
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 F. Hoffmann-La Roche Ltd
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Gilead Sciences Inc
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 GSK Plc
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Merck & Co Inc
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Pfizer Inc
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Shionogi & Co Ltd
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations
Access the Full A Market Report
Get segment-level forecasts, regional estimates, competitive benchmarking, company profiles and downloadable Excel datasets.
